News - Aegerion Pharmaceuticals, Rare diseases

Filter

Popular Filters

Aegerion receives US subpoena over USA sales of Juxtapid

Aegerion receives US subpoena over USA sales of Juxtapid

13-01-2014

US biopharma company Aegerion Pharmaceuticals has received a subpoena from the US Department of Justice…

Aegerion PharmaceuticalsFinancialJuxtapidLegalPharmaceuticalRare diseasesUSA

Aegerion gains European approval for rare disease drug

05-08-2013

The European Commission has approved US biopharma company Aegerion Pharmaceuticals' (Nasdaq: AEGR) Lojuxta…

Aegerion PharmaceuticalsBiotechnologyCardio-vascularEuropeJuxtapidKynamroLojuxtalomitapidePharmaceuticalRare diseasesRegulation

FDA approves Aegerion's new orphan drug Juxtapid for rare cholesterol disorder

28-12-2012

The US Food and Drug Administration has recently approved emerging US biotech firm Aegerion Pharmaceuticals'…

Aegerion PharmaceuticalsBiotechnologyCardio-vascularJuxtapidlomitapideNorth AmericaRare diseasesRegulation

Aegerion files for lomitapide approval in USA and Europe

07-03-2012

Emerging US biotech firm Aegerion Pharmaceuticals (Nasdaq: AEGR) has submitted a New Drug Application…

Aegerion PharmaceuticalsBiotechnologyEuropelomitapideNorth AmericaRare diseasesRegulation

Back to top